Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| fibroblast | 21 studies | 29% ± 14% | |
| endothelial cell | 14 studies | 30% ± 11% | |
| pericyte | 9 studies | 35% ± 15% | |
| capillary endothelial cell | 8 studies | 34% ± 11% | |
| endothelial cell of vascular tree | 7 studies | 37% ± 16% | |
| vein endothelial cell | 6 studies | 27% ± 12% | |
| myofibroblast cell | 4 studies | 19% ± 4% | |
| endothelial cell of artery | 4 studies | 27% ± 5% | |
| smooth muscle cell | 4 studies | 21% ± 3% | |
| astrocyte | 3 studies | 25% ± 8% |
Insufficient scRNA-seq data for expression of SERPINE1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 93% | 37105.36 | 539 / 578 | 83% | 171.89 | 964 / 1155 |
| liver | 59% | 23041.78 | 134 / 226 | 72% | 147.38 | 293 / 406 |
| breast | 36% | 7775.73 | 167 / 459 | 75% | 88.22 | 840 / 1118 |
| kidney | 40% | 7079.55 | 36 / 89 | 66% | 260.99 | 598 / 901 |
| ovary | 59% | 8023.46 | 107 / 180 | 47% | 64.49 | 200 / 430 |
| pancreas | 11% | 693.43 | 35 / 328 | 95% | 367.40 | 169 / 178 |
| adrenal gland | 45% | 5204.99 | 117 / 258 | 59% | 113.76 | 136 / 230 |
| bladder | 24% | 6456.57 | 5 / 21 | 75% | 210.58 | 379 / 504 |
| skin | 41% | 70133.84 | 737 / 1809 | 58% | 118.53 | 273 / 472 |
| esophagus | 12% | 1170.30 | 173 / 1445 | 86% | 283.59 | 158 / 183 |
| blood vessel | 98% | 60820.92 | 1302 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 51% | 8894.28 | 330 / 653 | 42% | 44.72 | 254 / 605 |
| stomach | 24% | 2833.51 | 85 / 359 | 63% | 78.15 | 181 / 286 |
| uterus | 20% | 1915.44 | 34 / 170 | 64% | 132.85 | 294 / 459 |
| adipose | 77% | 22909.12 | 931 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 71% | 181.06 | 32 / 45 |
| intestine | 18% | 2577.13 | 175 / 966 | 52% | 97.09 | 275 / 527 |
| prostate | 29% | 5306.82 | 71 / 245 | 39% | 37.74 | 198 / 502 |
| brain | 1% | 135.43 | 39 / 2642 | 41% | 100.84 | 289 / 705 |
| heart | 41% | 12252.65 | 356 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 38% | 35.86 | 11 / 29 |
| spleen | 11% | 1032.57 | 27 / 241 | 0% | 0 | 0 / 0 |
| muscle | 8% | 599.88 | 68 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 2% | 146.56 | 15 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 1% | 1.03 | 1 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0001525 | Biological process | angiogenesis |
| GO_2000352 | Biological process | negative regulation of endothelial cell apoptotic process |
| GO_0014912 | Biological process | negative regulation of smooth muscle cell migration |
| GO_0010469 | Biological process | regulation of signaling receptor activity |
| GO_0061045 | Biological process | negative regulation of wound healing |
| GO_1901331 | Biological process | positive regulation of odontoblast differentiation |
| GO_0010951 | Biological process | negative regulation of endopeptidase activity |
| GO_0045766 | Biological process | positive regulation of angiogenesis |
| GO_0051918 | Biological process | negative regulation of fibrinolysis |
| GO_0050829 | Biological process | defense response to Gram-negative bacterium |
| GO_0010757 | Biological process | negative regulation of plasminogen activation |
| GO_0090026 | Biological process | positive regulation of monocyte chemotaxis |
| GO_0097187 | Biological process | dentinogenesis |
| GO_2000098 | Biological process | negative regulation of smooth muscle cell-matrix adhesion |
| GO_0090399 | Biological process | replicative senescence |
| GO_0033629 | Biological process | negative regulation of cell adhesion mediated by integrin |
| GO_0042730 | Biological process | fibrinolysis |
| GO_0048260 | Biological process | positive regulation of receptor-mediated endocytosis |
| GO_0035491 | Biological process | positive regulation of leukotriene production involved in inflammatory response |
| GO_0032757 | Biological process | positive regulation of interleukin-8 production |
| GO_0030194 | Biological process | positive regulation of blood coagulation |
| GO_0071222 | Biological process | cellular response to lipopolysaccharide |
| GO_1902042 | Biological process | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors |
| GO_0030336 | Biological process | negative regulation of cell migration |
| GO_0030195 | Biological process | negative regulation of blood coagulation |
| GO_0050729 | Biological process | positive regulation of inflammatory response |
| GO_0061044 | Biological process | negative regulation of vascular wound healing |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_1904090 | Cellular component | peptidase inhibitor complex |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0097180 | Cellular component | serine protease inhibitor complex |
| GO_0031093 | Cellular component | platelet alpha granule lumen |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| GO_0005102 | Molecular function | signaling receptor binding |
| GO_0002020 | Molecular function | protease binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | SERPINE1 |
| Protein name | Plasminogen activator inhibitor 1 (PAI) (PAI-1) (Endothelial plasminogen activator inhibitor) (Serpin E1) |
| Synonyms | PLANH1 PAI1 |
| Description | FUNCTION: Serine protease inhibitor. Inhibits TMPRSS7 . Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots . As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading . Acts as a regulator of cell migration, independently of its role as protease inhibitor . It is required for stimulation of keratinocyte migration during cutaneous injury repair . It is involved in cellular and replicative senescence . Plays a role in alveolar type 2 cells senescence in the lung (By similarity). Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis . . |
| Accessions | P05121 ENST00000223095.5 [P05121-1] |
